Premium
Review Article: Efficacy and safety of rabeprazole in treating gastroesophageal reflux disease
Author(s) -
LIM PWY,
GOH KL
Publication year - 2004
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.2004.03592.x
Subject(s) - rabeprazole , medicine , reflux , disease , intensive care medicine , gastroenterology , proton pump inhibitor
Proton pump inhibitors (PPI) are the mainstay of gastroesophageal reflux disease (GERD) treatment. They have a good efficacy and short‐ and long‐term safety profile. Rabeprazole is a second generation PPI with rapid onset of action that quickly relieves symptoms of GERD. Rabeprazole consistently and profoundly inhibits gastric acid secretion. Its metabolism is less dependent on CYP4502C19 system and therefore is the least affected among all PPIs by CYP4502C19 genetic polymorphism. Recent studies have also indicated that rabeprazole on‐demand is cost effective in preventing non‐erosive reflux disease (NERD) symptom relapse.